<DOC>
	<DOCNO>NCT00442117</DOCNO>
	<brief_summary>This study open-label , parallel-group comparison Mometasone Furoate Dry Powder Inhaler ( MF-DPI ) 200 mcg daily even two puff vs. Budesonide Dry Powder Inhaler ( BUD-DPI ) 200 mcg twice daily two puff time patient previously treat inhaled corticosteroid ( ICS ) without ICS diagnose mild persistent moderate persistent asthma ( classified Global Initiative For Asthma , 2005 ) previous 4 week . The primary efficacy endpoint percent change baseline FEV1 .</brief_summary>
	<brief_title>A Comparison Mometasone Furoate DPI Versus Budesonide DPI Budesonide DPI Asthmatics ( Study P04880 )</brief_title>
	<detailed_description />
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Subjects must 12 year age old either gender , ( parent/guardian subject age 20 ) must demonstrate willingness sign write inform consent . Subjects must history asthma least 6 month . The subject must diagnose mild persistent moderate persistent asthma his/her FEV1 must &gt; = 60 % predict normal Screening Baseline visit , shortacting inhale beta agonist withhold least six hour longacting inhaled beta agonist withhold least 12 hour . Subjects must demonstrate increase absolute FEV1 &gt; = 12 % , absolute volume increase least 200 mL , reversibility test Screening visit , historically within past 12 month ; Subjects without document absolute FEV1 &gt; = 12 % reversibility test within past 12 month need demonstrate positive result Methacholine challenge test . If Subjects ICS treatment use ICS daily basis least 4 week prior Screening . For two week prior Screening , subject must stable regimen ICS . Each ICS dose show following : Flunisolide 1000 2000 mcg/day Budesonide 400 800 mcg/day Triamcinolone acetonide 600 1600 mcg/day Beclomethasone Dipropionate 252 840 mcg/day Fluticasone propionate 200 500 mcg/day Women childbearing potential must negative urine ( hCG ) pregnancy test day randomization ( Baseline visit ) . Women childbearing potential ( include woman less 1 year postmenopausal ) must use agree use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) become sexually active . Subjects must understand able adhere visit schedule enter information daily diary . Female subject pregnant , breastfeeding , premenarcheal . Subjects heavy smoker ( 10 pack year ) smoke within previous 6 month . Subjects require daily alternate day oral corticosteroid treatment total 14 day 3 month immediately prior Screening visit , and/or subject require course systemic corticosteroid within previous month . Subjects use Leukotriene modifier within 2 week screen . Subjects take immunosuppressive agent within previous 3 month . Subjects use daily nebulized ÃŸ2adrenergic agonist . Subjects either asthma exacerbation clinically relevant change asthma medication within last 4 week . Subjects admit hospital asthma control within previous 3 month need emergency service asthma within previous 6 month . Subjects require ventilator support respiratory failure secondary asthma within last 5 year . Subjects use investigational drug 30 day prior Baseline , subject treated investigational antibody asthma 90 day prior Baseline . Subjects allergic idiosyncratic reaction corticosteroid . Subjects evidence clinically significant oropharyngeal candidiasis Screening Baseline . Subjects clinically significant disorder cardiovascular , neurologic , hematologic , gastrointestinal , cerebrovascular , immunologic system , respiratory disease asthma ( e.g . COPD ) , disorder may interfere study evaluation affect subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>